trial

An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults

NCTId NCT03094429
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2, Phase 3 · Recruiting
Enrollment 287 (estimated)
Sponsored by SyneuRx International (Taiwan) Corp
Primary completion 2026-09-30
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2, Phase 3
Status
Recruiting
Enrollment
287 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2017-03-29
Primary completion
2026-09-30
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
NaBen®

Sponsors

SyneuRx International (Taiwan) CorpLead Sponsor
Amarex Clinical ResearchCollaborator

Sites

1 total
Pasadena, United States

Linked catalysts

1
An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled — primary completion2026-09-30

Facts & assertions

4 sourced
Enrollment
287
Phase
PHASE2,PHASE3
Primary Completion Date
2026-09-30
Status
RECRUITING
relationships
The graph out of here
drug
NaBen®
drug
lead_sponsor
SyneuRx International (Taiwan) Corp
company
collaborator
Amarex Clinical Research
company
indication
Refractory Schizophrenia
indication
Schizophrenia, Treatment-Resistant
indication